$0.58
1.55% today
Nasdaq, Jul 17, 08:16 pm CET
ISIN
US70387R1068
Symbol
PAVM

PAVmed, Inc. Target price 2025 - Analyst rating & recommendation

PAVmed, Inc. Classifications & Recommendation:

Buy
88%
Hold
13%

PAVmed, Inc. Price Target

Target Price $11.73
Price $0.58
Potential
Number of Estimates 4
4 Analysts have issued a price target PAVmed, Inc. 2026 . The average PAVmed, Inc. target price is $11.73. This is higher than the current stock price. The highest price target is
$19.95 3,369.57%
register free of charge
, the lowest is .
A rating was issued by 8 analysts: 7 Analysts recommend PAVmed, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the PAVmed, Inc. stock has an average upside potential 2026 of . Most analysts recommend the PAVmed, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2030

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 3.00 0.15
22.45% 95.02%
EBITDA Margin -1,443.00% -12,627.99%
46.32% 775.12%
Net Margin 1,065.67% 2,060.48%
139.40% 93.35%

4 Analysts have issued a sales forecast PAVmed, Inc. 2025 . The average PAVmed, Inc. sales estimate is

$149k
Unlock
. This is
92.49% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$203k 89.81%
Unlock
, the lowest is
$98.0k 95.08%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $3.0m 22.45%
2025
$149k 95.02%
Unlock
2026
$830k 455.76%
Unlock
2027
$187m 22,454.50%
Unlock
2028
$243m 29.96%
Unlock
2029
$312m 28.00%
Unlock
2030
$389m 25.02%
Unlock

3 Analysts have issued an PAVmed, Inc. EBITDA forecast 2025. The average PAVmed, Inc. EBITDA estimate is

$-18.9m
Unlock
. This is
47.16% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-19.4m 45.60%
Unlock
, the lowest is
$-18.1m 49.23%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-43.3m 34.27%
2025
$-18.9m 56.41%
Unlock
2026
$-18.6m 1.62%
Unlock

EBITDA Margin

2024 -1,443.00% 46.32%
2025
-12,627.99% 775.12%
Unlock
2026
-2,235.87% 82.29%
Unlock

4 PAVmed, Inc. Analysts have issued a net profit forecast 2025. The average PAVmed, Inc. net profit estimate is

$3.1m
Unlock
. This is
95.75% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$3.2m 95.62%
Unlock
, the lowest is
$3.0m 95.91%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $32.0m 148.24%
2025
$3.1m 90.37%
Unlock
2026
$-7.5m 344.48%
Unlock

Net Margin

2024 1,065.67% 139.40%
2025
2,060.48% 93.35%
Unlock
2026
-906.49% 143.99%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2030

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 0.50 0.18
105.46% 64.00%
P/E 3.13
EV/Sales 90.34

4 Analysts have issued a PAVmed, Inc. forecast for earnings per share. The average PAVmed, Inc. EPS is

$0.18
Unlock
. This is
86.96% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$0.19 86.23%
Unlock
, the lowest is
$0.18 86.96%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $0.50 105.46%
2025
$0.18 64.00%
Unlock
2026
$-0.45 350.00%
Unlock

P/E ratio

Current 0.42 456.46%
2025
3.13 651.14%
Unlock
2026
-1.28 140.89%
Unlock

Based on analysts' sales estimates for 2025, the PAVmed, Inc. stock is valued at an EV/Sales of

90.34
Unlock
and an P/S ratio of
66.52
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 6.79 5.27%
2025
90.34 1,230.53%
Unlock
2026
16.26 82.00%
Unlock
2027
0.07 99.56%
Unlock
2028
0.06 23.02%
Unlock
2029
0.04 21.98%
Unlock
2030
0.03 19.86%
Unlock

P/S ratio

Current 5.00 136.23%
2025
66.52 1,231.13%
Unlock
2026
11.97 82.00%
Unlock
2027
0.05 99.56%
Unlock
2028
0.04 23.16%
Unlock
2029
0.03 21.81%
Unlock
2030
0.03 20.06%
Unlock

Current PAVmed, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Ascendiant Capital
Locked
Locked
Locked Jun 06 2025
Ascendiant Capital
Locked
Locked
Locked Apr 21 2025
Ascendiant Capital
Locked
Locked
Locked Dec 09 2024
Ascendiant Capital
Locked
Locked
Locked Sep 10 2024
Analyst Rating Date
Locked
Ascendiant Capital:
Locked
Locked
Jun 06 2025
Locked
Ascendiant Capital:
Locked
Locked
Apr 21 2025
Locked
Ascendiant Capital:
Locked
Locked
Dec 09 2024
Locked
Ascendiant Capital:
Locked
Locked
Sep 10 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today